Table 1.

Results of logistic regression with backward elimination for a major clinical response to adalimumab at week 12 as defined by BASDAI 50, ASAS40, and ASAS partial remission.

Predictors	BASDAI 50		ASAS40		ASAS Partial Remission
Predictors	OR (95% CI)	p	OR (95% CI)	p	OR (95% CI)	p
Age, yrs	0.97 (0.96–0.98)	< 0.001	0.96 (0.95–0.97)	< 0.001	0.96 (0.95–0.97)	< 0.001
HLA-B27-positive vs negative	1.77 (1.25–2.49)	0.001	1.60 (1.12–2.28)	0.009	2.20 (1.40–3.45)	< 0.001
Prior TNF antagonist therapy^*	0.35 (0.26–0.48)	< 0.001	0.32 (0.24–0.44)	< 0.001	0.32 (0.21–0.47)	< 0.001
CRP, mg/dl	1.23 (1.15–1.32)	< 0.001	1.17 (1.09–1.25)	< 0.001	1.20 (1.12–1.28)	< 0.001
BASFI, 0–10	0.89 (0.83–0.96)	0.003	—	—	0.77 (0.72–0.83)	< 0.001
BASMI, 0–10	—	—	—	—	0.91 (0.85–0.99)	0.019
Total back pain, 0–100 mm VAS	0.99 (0.98–1.00)	0.012	—	—	—	—
Morning stiffness, 0–10	—	—	1.11 (1.04–1.20)	0.004	—	—
Physician global assessment of disease activity, 0–100 mm VAS	—	—	0.99 (0.98–1.00)	0.016	—	—
Patient global assessment of disease activity, 0–100 mm VAS	—	—	1.02 (1.01–1.02)	< 0.001	—	—
Use of glucocorticoids^*	—	—	0.67 (0.45–1.00)	0.048	—	—

↵* Yes versus no, selection level, 0.05. AS: ankylosing spondylitis, ASAS40: Assessment in Spondyloarthritis International Society 40% response, BASDAI 50: Bath AS Disease Activity Index 50% response, BASFI: Bath AS Functional Index, BASMI: Bath AS Metrology Index, CRP: C-reactive protein, TNF: tumor necrosis factor, VAS: visual analog scale.